PMID- 7857318
OWN - NLM
STAT- MEDLINE
DCOM- 19950314
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 49
IP  - 3
DP  - 1995 Jan 31
TI  - Heterogeneity of circulating and exudated polymorphonuclear leukocytes in 
      superoxide-generating response to cyclic AMP and cyclic AMP-elevating agents. 
      Investigation of the underlying mechanism.
PG  - 315-22
AB  - It has been found that cyclic AMP and cyclic AMP-elevating agents inhibit 
      formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated superoxide production 
      from polymorphonuclear leukocytes (PMNs). The quantitative differences of this 
      inhibitory effect on human and rabbit blood versus human salivary and rabbit 
      peritoneal (tissue) PMNs were investigated. PMNs from all sources showed the same 
      pattern of fMLP-stimulated superoxide generation, although it was slightly higher 
      in tissue PMNs. However, treatment with salbutamol differentially blunted 
      fMLP-stimulated superoxide production from blood PMNs compared with tissue PMNs 
      in both human and rabbit. While it could inhibit production from blood PMNs by 
      30-60%, it had only a negligible effect on generation from tissue PMNs. 
      Similarly, forskolin, phosphodiesterase IV inhibitor Ro-201724, and dibutryl 
      cyclic AMP showed significantly higher inhibitory effects on superoxide 
      generation from blood PMNs than tissue PMNs in both species. beta-Adrenergic 
      receptors, cyclic AMP accumulation, and protein kinase A activity were 
      investigated in blood versus tissue PMNs to clarify the mechanism underlying the 
      above-mentioned differences. At the beta-adrenergic receptor level, no 
      significant changes were detected in the number or the binding affinity of the 
      receptors in tissue versus blood PMNs of human and rabbit. On the other hand, 
      cyclic AMP accumulation was significantly higher in response to salbutamol and 
      Ro-201724 in fMLP-stimulated blood versus tissue PMNs in human and rabbit. At the 
      same time, blood PMNs showed significantly higher cyclic AMP-dependent protein 
      kinase A activity than tissue PMNs in human and rabbit. We concluded that tissue 
      PMNs are less responsive to the effect of cyclic AMP-elevating agents in terms of 
      fMLP-stimulated superoxide inhibition. This is due to differences, at least, at 
      two levels. The first is lower accumulation of cyclic AMP and the second is lower 
      protein kinase A activity in tissue versus blood PMNs.
FAU - al-Essa, L Y
AU  - al-Essa LY
AD  - Department of Pharmacology, Gifu University School of Medicine, Japan.
FAU - Niwa, M
AU  - Niwa M
FAU - Kohno, K
AU  - Kohno K
FAU - Nozaki, M
AU  - Nozaki M
FAU - Tsurumi, K
AU  - Tsurumi K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 11062-77-4 (Superoxides)
RN  - 1F7A44V6OU (Colforsin)
RN  - 29925-17-5 (4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases)
RN  - QF8SVZ843E (Albuterol)
SB  - IM
MH  - 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone/pharmacology
MH  - Albuterol/pharmacology
MH  - Animals
MH  - Colforsin/pharmacology
MH  - Cyclic AMP/biosynthesis/*pharmacology
MH  - Cyclic AMP-Dependent Protein Kinases/blood
MH  - Exudates and Transudates/cytology
MH  - Humans
MH  - N-Formylmethionine Leucyl-Phenylalanine/antagonists & inhibitors/pharmacology
MH  - Neutrophils/*drug effects/metabolism
MH  - Peritoneum
MH  - Rabbits
MH  - Saliva/cytology
MH  - Superoxides/*metabolism
EDAT- 1995/01/31 00:00
MHDA- 1995/01/31 00:01
CRDT- 1995/01/31 00:00
PHST- 1995/01/31 00:00 [pubmed]
PHST- 1995/01/31 00:01 [medline]
PHST- 1995/01/31 00:00 [entrez]
AID - 0006-2952(94)00506-H [pii]
AID - 10.1016/0006-2952(94)00506-h [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1995 Jan 31;49(3):315-22. doi: 10.1016/0006-2952(94)00506-h.